TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04935281

Intervention type: OTHER
Intervention: percutaneous repair with an intraoperative assisted ultrasound
Description: Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .

Intervention type: OTHER
Intervention: percutaneous repair without an intraoperative assisted ultrasound
Description: For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
Study: NCT01069016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral nerve modulation
Description: For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral nerve modulation
Description: For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation
Description: For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation
Description: For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
Study: NCT02651467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)
Description: 1.5% w/w KOX, 0ppm F, pH 7.0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)
Description: 2.0% w/w KOX, 45ppm F, pH 4.5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )
Description: 0% w/w KOX 0ppm F, pH 4.5
Study: NCT01031381

Intervention type: DRUG
Group type: OTHER
Intervention: RAD001
Description: RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.

Intervention type: DRUG
Group type: OTHER
Intervention: bevacizumab
Description: bevacizumab will be administered intravenously (IV) once every 14 days.
Study: NCT00334685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine + Pregabalin
Description: \[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Study: NCT01999153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mL topically used during alginate dressing NAROPEINE
Description: 20 mL topically used during alginate dressing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 20 mL topically used during alginate dressing NaCl
Description: 20 mL topically used during alginate dressing
Study: NCT03349931

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction and detection of Aspergillus fumigatus in serum samples
Description: Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
Study: NCT00810914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine epidural
Description: bupivicaine continuous epidural infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine epidural infusion patient epidural
Description: bupivicaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine
Description: patient controlled anesthesia only
Study: NCT01315964

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plant stanol ester
Description: 3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant stanol ester
Description: 3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
Study: NCT00590850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF with Plate and Screws
Description: ORIF with plate and screws

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pin Fixation
Description: Clavicle fixation with clavicle pin
Study: NCT00111982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liatermin
Description: Liatermin
Study: NCT03564431

Intervention type: DEVICE
Intervention: Magnetic resonance
Description: magnetic resonance spectrum of brain

Intervention type: DEVICE
Intervention: Magnetic resonance
Description: magnetic resonance spectrum of brain

Intervention type: DEVICE
Intervention: Magnetic resonance
Description: magnetic resonance spectrum of brain

Intervention type: DEVICE
Intervention: Magnetic resonance
Description: magnetic resonance spectrum of brain
Study: NCT00904397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm®
Description: Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
Study: NCT02624960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accucinch Implant
Description: Percutaneous implantation of the Accucinch Implant in the mitral subannular space
Study: NCT02995031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT02884882

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Emotional induction
Description: Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.

Intervention type: OTHER
Group type: OTHER
Intervention: Emotional induction
Description: Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
Study: NCT03278756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive control training
Description: 10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control training
Description: 10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
Study: NCT03683160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Augmented Mobility Program
Description: CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
Study: NCT04524806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stabilization splint
Description: Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stabilization splint
Description: Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
Study: NCT03676998

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of diaphragm function
Description: A bilateral magnetic stimulation induces a non voluntary diaphragm contraction and a drop in airway pressure that is measured.
Study: NCT02029001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg BID)
Description: Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg QD)
Description: Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg BID)
Description: Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg QD)
Description: Patients whose tumor harbors mutations or amplifications of HER2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg QD)
Description: Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT\* or amplification /translocation of the genes and/or of the ligands.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg BID)
Description: ATM, BAP1 et BRIP1 Mutation only if double hit documented; BRCA2, BRCA1, RAD51C, PALB2, RAD51D Mutation; BRCA1, BRCA2, ATM and BAP1 Loss; BRCA1, BRCA2, ATM and BAP 1 : mutation and heterozygote deletion. except for patients eligible to olaparib's available labels and reimbursements in France.~NOTE : only prostate cancer with RECIST 1.1 evaluable disease are eligible until the French price and reimbursement

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Description: Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
Study: NCT01823146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin spray
Description: single dose of 24 IU oxytocin, self-administered intranasally (IN)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
Study: NCT02552784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: data assessment of the state of health and quality of life of patients and their families
Description: Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
Study: NCT04123652

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992
Description: An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours.
Study: NCT02698878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lupin protein
Description: 19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
Study: NCT01025206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-505
Description: Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
Study: NCT03703479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous blood clot made from the patient own clot without any additive
Description: advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
Study: NCT03761784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-3
Description: Once a day topical cream
Study: NCT01719055

Intervention type: DEVICE
Intervention: neurostimulation system
Description: Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
Study: NCT04155827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIT
Description: Sprint interval training of 4\*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIT
Description: Sprint interval training of 4\*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
Study: NCT02280187

Intervention type: PROCEDURE
Intervention: Spine Fusion
Description: All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
Study: NCT04383717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamisole and isoprinosine
Description: oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin and hydroxychloroquine
Description: oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
Study: NCT01405274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy treatment bi-weekly, delivered at the child's home
Study: NCT03969316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block, Quadratus lumborum block
Description: The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block, Quadratus lumborum block
Description: The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
Study: NCT02681406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACHESS
Description: Smartphone based additions focused application, encouraging social support
Study: NCT02698878

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEPHAISTOS unloading orthotic device
Description: Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
Study: NCT02698878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPHAISTOS unloading orthotic device
Description: Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
Study: NCT02681406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMC
Description: Brief telephone monitoring and counseling
Study: NCT02587455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab - Trial Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab - Trial Treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy - Standard Treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy - Standard Treatment
Study: NCT04638660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Ophthalmic Solution 0.75%
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Ophthalmic Solution Vehicle (Placebo)
Description: Topical sterile ophthalmic solution
Study: NCT03429660

Intervention type: OTHER
Intervention: Medical information
Description: The information collected are about :~* Introduction or non-introduction of treatment~* Cumulative dose of treatment~* Drug dispensation and withdrawal~* Hospitalization reason~* Safety information~* Demographic data (date of death)
Study: NCT03781843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block with lidocaine
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Genicular nerve block with saline
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Genicular nerve block with dextrose
Description: The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
Study: NCT00687895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical algorithm and microscopy diagnosis of malaria
Description: Clinical alogarithm~The content of the package included~1. description of signs and symptoms of malaria disease~2. history taking relevant to malaria and physical examination~3. identification of danger signs and severe illness for referral~4. appropriate treatment~5. counseling patients on the use of drugs.~Malaria microscopy. contents~1. make thick blood smears from patients with fever and stain with Giemsa~2. identify and count malaria parasites~3. maintain the microscope and store blood slides.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical algorithm and microscopy diagnosis of malaria
Description: Clinical alogarithm~The content of the package included~1. description of signs and symptoms of malaria disease~2. history taking relevant to malaria and physical examination~3. identification of danger signs and severe illness for referral~4. appropriate treatment~5. counseling patients on the use of drugs.~Malaria microscopy. contents~1. make thick blood smears from patients with fever and stain with Giemsa~2. identify and count malaria parasites~3. maintain the microscope and store blood slides.
Study: NCT02624674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-spectral Imaging Device (MSID)
Study: NCT02737280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy
Description: High flow nasal cannula therapy with Airvo (TM, Fisher \& Paykel Healthcare) device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedKit Finland - Usual oxygen therapy
Description: Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
Study: NCT03917459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril matching placebo
Description: Placebo to Enalapril 10 mg film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 10 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 matching placebo
Description: Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
Study: NCT02505763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strategy with thoracic ultrasound
Description: This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
Study: NCT03532061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamCare Program
Description: 6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Support Group
Description: 6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
Study: NCT00376064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide acetate and cabergoline/Octrotide and Somavert
Study: NCT01971242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: 2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
Study: NCT01622803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parallel stent
Description: bilateral parallel stent insertion (right and left side)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Y-stent (BONASTENT M-Hilar)
Description: Bilateral Y-stent insertion (stent in stent type)